<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Steroid 5-alpha-reductase 2 deficiency</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Steroid 5-alpha-reductase 2 deficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Steroid 5-alpha-reductase 2 deficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Olaf Hiort, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Steroid 5-alpha-reductase 2 deficiency, a 46,XY disorder or difference of sex development (DSD), is an autosomal recessive condition in which 46,XY subjects with bilateral testes and normal testosterone production have impaired virilization during embryogenesis due to diminished conversion of testosterone to dihydrotestosterone (DHT).</p><p>The clinical manifestations, pathogenesis, diagnosis, and treatment of 5-alpha-reductase deficiency are reviewed here. DSD due to defects in testosterone biosynthesis and in androgen receptor function are discussed elsewhere. A review of terminology for DSDs is also found separately (<a class="graphic graphic_table graphicRef118023" href="/z/d/graphic/118023.html" rel="external">table 1</a>) (See  <a class="medical medical_review" href="/z/d/html/7471.html" rel="external">"Diagnosis and treatment of disorders of the androgen receptor"</a> and  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action"</a> and  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Lipoid congenital adrenal hyperplasia'</a>.)</p><p class="headingAnchor" id="H886527753"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Steroid 5-alpha-reductase 2 deficiency was initially described in 1961 [<a href="#rid1">1</a>] and later in clusters around the world. One was a pedigree of 24 families with 38 affected males in the Dominican Republic, an area where consanguineous marriages are common [<a href="#rid2">2-4</a>]. In a subsequent report of forty 46,XY infants born with ambiguous genitalia in the Dominican Republic over a 10-year period, five (13 percent) were diagnosed with steroid 5-alpha-reductase 2 deficiency [<a href="#rid5">5</a>]. One of the five patients was traced to the original kindred of 38 affected subjects.</p><p>Additional clusters of patients have also been reported in Turkey [<a href="#rid6">6</a>] and Papua New Guinea [<a href="#rid7">7</a>], but steroid 5-alpha-reductase 2 deficiency is otherwise thought to be rare. The prevalence in the general population is unknown [<a href="#rid8">8</a>]. However, patients with steroid 5-alpha-reductase 2 deficiency have now been reported from a variety of countries and ethnic backgrounds [<a href="#rid9">9-11</a>]. A literature review identified 434 cases of 5-alpha-reductase 2 deficiency from 44 countries, mainly from Turkey (23 percent), China (17 percent), Italy (9 percent), and Brazil (7 percent) [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H886527461"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Individuals with steroid 5-alpha-reductase 2 deficiency are 46,XY with normal testosterone production but impaired virilization during embryogenesis, due to defective conversion of testosterone to dihydrotestosterone (DHT). The nature of the enzyme abnormality in this disorder was discovered when it was demonstrated that 5-alpha-reductase activity in cultured genital skin fibroblasts from affected subjects was reduced [<a href="#rid13">13</a>]. Cloning of the cDNAs that encode the enzymes revealed that there are two steroid 5-alpha-reductases, termed types 1 and 2, involved in human sex development [<a href="#rid14">14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Steroid 5-alpha-reductase type 2 enzyme is defective in subjects with the disorder, whereas the type 1 enzyme is normal. Reduced DHT formation in androgen target tissues impairs virilization of the male urogenital tract in embryogenesis. The low but measurable serum concentrations of DHT in affected subjects could be due either to residual activity of the mutant enzyme or the normal type 1 isoenzyme. Studies in families in which the type 2 enzyme is believed to be absent suggest that the DHT in the serum of these subjects is predominantly derived from the type 1 enzyme [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Virilization at the time of expected puberty in untreated subjects may be mediated by the increase in serum testosterone, which induces male-type body composition (muscle growth), or increase in DHT concentrations that occur at puberty through 5-alpha-reductase type 1.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testosterone and estrogen production are in the typical male range in 5-alpha-reductase 2 deficiency [<a href="#rid16">16</a>]. This explains why affected subjects do not develop permanent gynecomastia at the time of puberty. In contrast, gynecomastia at puberty is common in subjects with mutations of the androgen receptor (see <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action"</a>). In addition, a steroid 5-alpha-reductase type 3 has been described, which does play a role in congenital disorders of glycosylation, but not in sex development or virilization [<a href="#rid17">17,18</a>].</p><p></p><p class="headingAnchor" id="H886527467"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>This disorder is due to autosomal recessive loss of function mutations in the gene that encodes steroid 5-alpha-reductase type 2 (<em>SRD5A2</em>). Mutations are distributed throughout the coding region. Over 50 different mutations have been described [<a href="#rid15">15,19</a>]. Point mutations are responsible for most cases, but indels, splicing mutations, and larger deletions have also been reported [<a href="#rid12">12</a>]. Approximately 40 percent of subjects carry homozygous mutations, in keeping with the finding of frequent consanguinity in the families; the remainder are compound heterozygotes [<a href="#rid20">20</a>].</p><p>The disorder has worldwide distribution. Identical mutations have been detected in different ethnic groups. The R227Q mutation, which is associated with retention of approximately 3 percent of normal enzymatic activity, appears to be relatively frequent in Japanese populations and may cause micropenis rather than ambiguous genitalia [<a href="#rid21">21</a>]. In some instances, recurrent mutations are the consequence of a founder effect [<a href="#rid22">22</a>]. (See <a class="local">'Epidemiology'</a> above.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H110017744"><span class="h2">46,XY individuals</span><span class="headingEndMark"> — </span>The typical clinical features in 46,XY males with 5-alpha-reductase 2 deficiency are those reported in the two originally recognized families as well as others [<a href="#rid2">2,16,23</a>].</p><p class="headingAnchor" id="H4090405249"><span class="h3">Features at birth</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>External genitalia</strong> –<strong> </strong>The external genitalia often are predominately female at birth; however, the range of undervirilization may be from almost complete male with isolated microphallus and varying degrees of hypospadias to completely female with clitoromegaly or typical female genital appearance [<a href="#rid20">20,24</a>]. Although the degree of virilization of the external genitalia is variable, masculinization of nongenital tissues, eg, muscle, at puberty is normal.</p><p></p><p class="bulletIndent1">Approximately 55 percent of affected subjects have a blind-ending or pseudovagina in which the Wolffian ducts terminate in the upper vagina. In 40 percent, the Wolffian ducts terminate in the perineum on either side of the urethra. The remainder are considerably virilized, so that they have a predominantly male appearance at birth [<a href="#rid25">25</a>]. The testes are invariably outside the abdominal cavity either in the inguinal canals, labia majora, or scrotum, and spermatogenesis is often impaired.</p><p></p><p class="bulletIndent1">A wide spectrum of phallic size at birth was reported in a study of 55 patients with 5-alpha-reductase 2 deficiency [<a href="#rid20">20</a>]. No enlargement (typical female size clitoris) occurred in four (7.3 percent), a slight degree of enlargement (clitoromegaly) in 27 (49 percent), and a greater degree of enlargement but less than typical male size (microphallus) in 18 patients (33 percent). Of note, 40 of the patients (72 percent) were initially assigned to female sex.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Internal urogenital tract</strong> –<strong> </strong>The internal urogenital tract is typical male, consisting of epididymides, vasa deferentia, seminal vesicles, and ejaculatory ducts that empty into a blind-ending vagina. The absence of müllerian duct derivatives indicates that anti-müllerian hormone is produced and acts normally. (See  <a class="medical medical_review" href="/z/d/html/7472.html" rel="external">"Typical sex development"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gynecomastia</strong> –<strong> </strong>Gynecomastia, which is the hallmark of partial androgen insensitivity, is very rare in 5-alpha-reductase deficiency. (See  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action", section on 'Partial androgen insensitivity (PAIS)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biochemical features</strong> –<strong> </strong>As adults, concentrations of serum testosterone and estradiol are similar to those in normal men. The level of serum luteinizing hormone (LH) is normal in approximately one-half of subjects and slightly elevated in the rest. Levels of serum follicle-stimulating hormone (FSH) may be elevated.</p><p></p><p class="bulletIndent1">Because of the defect in 5-alpha-reductase 2, the ratio of serum testosterone to dihydrotestosterone (DHT) is increased basally in adults and after administration of human chorionic gonadotropin (hCG) in childhood [<a href="#rid26">26</a>]. However, laboratory results may be nondiagnostic; therefore, molecular genetic analysis has been advocated for diagnosis [<a href="#rid20">20,26</a>], even in developing countries [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone density</strong> –<strong> </strong>One report of four individuals diagnosed as adults with intact testes found normal lumbar and hip bone mineral density in three individuals and mild lumbar osteopenia in the fourth [<a href="#rid28">28</a>]. In another study of 16 adult subjects with the disorder, hip bone mineral density was not significantly different than a reference male population [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H110017677"><span class="h3">Gender role change at puberty</span><span class="headingEndMark"> — </span>In the past, when affected 46,XY children were raised initially as female, gender role behavior changed to male at the time of expected puberty in a variable percentage of patients. In a large extended kindred from the Dominican Republic, 18 of 19 subjects initially raised as females subsequently changed gender role behavior to male at the time of puberty [<a href="#rid30">30</a>]. Similar results were described in a report from China; almost all patients from 11 families changed from female to male gender after puberty [<a href="#rid31">31</a>]. In other reports, however, only 50 to 60 percent of affected individuals assigned female sex in infancy who then virilized in puberty changed their gender role behavior to male [<a href="#rid8">8,32</a>]. The percentage of patients changing gender role was much lower (12.5 percent) in one report from France [<a href="#rid20">20</a>].</p><p>The change in gender role behavior is not unique to this disorder and has occurred in undervirilized 46,XY individuals with 17-beta-hydroxysteroid dehydrogenase 3 deficiency and other causes of impaired testosterone synthesis, and in subjects with mixed gonadal dysgenesis (45,X/46,XY difference of sex development [DSD]) [<a href="#rid33">33,34</a>]. However, change in gender role behavior is rare in subjects with androgen-receptor disorders. (See  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">46,XX individuals</span><span class="headingEndMark"> — </span>Women with 5-alpha-reductase 2 deficiency have also been described [<a href="#rid35">35,36</a>]. Three homozygous 46,XX women (siblings of the Dominican kindred described above) with 5-alpha-reductase 2 deficiency were identified based upon urinary steroid analyses and genotyping [<a href="#rid36">36</a>].</p><p>Biochemical features included elevated urinary testosterone levels and increased testosterone to DHT ratios. They had a typical female phenotype but they had absent arm or leg hair and a decrease in axillary and pubic hair (due to low DHT). They all experienced late menarche (ages 15 to 18 years) but then had normal menstrual function and fertility. These observations suggest that DHT plays an important role in the growth of normal body hair and pathogenesis of hirsutism in women. (See  <a class="medical medical_review" href="/z/d/html/7439.html" rel="external">"Pathophysiology and causes of hirsutism"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Definitive diagnosis requires sequencing the DNA of the gene (<em>SRD5A2)</em> that encodes steroid 5-alpha-reductase 2. The diagnosis is suggested by the characteristic clinical features and is further supported by an elevated ratio (&gt;20) of plasma testosterone to dihydrotestosterone (DHT) in 46,XY individuals after the age of puberty, or in infants and prepubertal subjects after administration of human chorionic gonadotropin (hCG). The diagnosis may be first suspected in infants with atypical genitalia or in adolescents or young adults with the characteristic phenotype. (See <a class="local">'46,XY individuals'</a> above and  <a class="medical medical_review" href="/z/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p>Adolescents who are not diagnosed in infancy are typically individuals who were initially assigned to a female sex, but then present at the time of puberty with marked masculinization and phallic growth. Further evaluation then demonstrates a blind vaginal pouch; the absence of a uterus; and bilateral, usually inguinal, testes.</p><p class="headingAnchor" id="H886528548"><span class="h2">Laboratory assessment</span></p><p class="headingAnchor" id="H886528763"><span class="h3">Infants and prepubertal subjects</span><span class="headingEndMark"> — </span>Measurement of basal serum concentrations of testosterone and DHT is <strong>not</strong> sufficient for diagnosis before the expected age of puberty, because available assays to measure the low levels of testosterone and DHT in infants and prepubertal children are inaccurate. To get reliable results in this age group, serum testosterone and DHT must be measured before and after multiple injections of human chorionic gonadotropin (hCG) [<a href="#rid26">26,37,38</a>]. However, we suggest genetic testing rather than hCG stimulation/biochemical testing for the definitive diagnosis [<a href="#rid39">39</a>]. The evaluation of the patient with a DSD is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p class="headingAnchor" id="H886528555"><span class="h3">Adolescents and adults</span><span class="headingEndMark"> — </span>Measurement of basal concentrations of serum testosterone and DHT is usually sufficient for diagnosis after the expected age of puberty, because of the higher values of testosterone in this age group.</p><p class="bulletIndent1"><span class="glyph">●</span>The ratio of serum testosterone to DHT was &gt;20 in affected subjects in the extended kindred from the Dominican Republic [<a href="#rid4">4</a>] and in another nine unrelated Brazilian families<strong><em> </em></strong>(<a class="graphic graphic_figure graphicRef50253" href="/z/d/graphic/50253.html" rel="external">figure 1</a>) [<a href="#rid38">38</a>]. In the latter group, the ratio ranged from 35 to 84 in affected subjects as compared with 8 to 16 in normal subjects. In adults, measurement of the ratio of serum testosterone to DHT after administration of hCG or testosterone does <strong>not </strong>increase discrimination between affected and normal men (<a class="graphic graphic_figure graphicRef50253" href="/z/d/graphic/50253.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Definitive diagnosis of the mutation in the <em>SRD5A2</em> gene encoding steroid 5-alpha-reductase 2 enzyme should be made by DNA analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cultures of genital skin fibroblasts should no longer be performed. They were done in the past to study enzyme characteristics, but these studies are invasive, costly, time-consuming, and, with the availability of molecular genetic diagnostics, inappropriate.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Defects in testosterone biosynthesis and partial defects in androgen receptor function can cause phenotypes that are similar to those found in subjects with 5-alpha-reductase deficiency. (See  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action"</a> and  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'CYP17A1 deficiencies'</a>.)</p><p>There are, however, important clinical differences among these disorders.</p><p class="bulletIndent1"><span class="glyph">●</span>17-beta-hydroxysteroid dehydrogenase 3 deficiency is a hereditary condition of testosterone biosynthesis that results in a phenotype similar to 5-alpha-reductase deficiency but greater impairment in virilization of the external genitalia than of the internal urogenital tract. In this form of 46,XY difference of sex development (DSD), serum testosterone concentrations are often in the lower typical male range, whereas serum concentrations of androstenedione, the precursor before the enzymatic block, are elevated several-fold [<a href="#rid40">40,41</a>]. Many different mutations can cause 17-beta-hydroxysteroid dehydrogenase 3 deficiency [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/118045.html" rel="external">"Causes of differences of sex development", section on 'Conditions affecting androgen synthesis or response'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Partial defects in androgen-receptor function can cause impaired external virilization and result in incomplete development of the male urogenital tract, including ambiguous genitalia. In contrast to 5-alpha-reductase deficiency, these disorders are usually associated with development of gynecomastia at the time of expected puberty. (See  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action"</a>.)</p><p></p><p class="bulletIndent1">Normal ratios of urinary 5-beta- to 5-alpha-reduced metabolites (measured in specialized laboratories) and testosterone to DHT in serum can be useful; however, only genetic analysis of the androgen receptor gene and the<em> SRD5A2</em> gene can provide a definitive diagnosis [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/7458.html" rel="external">"Pathogenesis and clinical features of disorders of androgen action"</a> and  <a class="medical medical_review" href="/z/d/html/7471.html" rel="external">"Diagnosis and treatment of disorders of the androgen receptor"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management is primarily dependent upon the phenotypic findings and sex assignment at the time of diagnosis. As noted above, most affected newborns are now assigned the male sex at birth [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H886528933"><span class="h2">Initial sex assignment</span><span class="headingEndMark"> — </span>The issue of sex assignment in the newborn in this condition is complex because historically ≥50 percent of individuals assigned the female sex have undergone a change in social gender (gender role behavior) later in life [<a href="#rid33">33</a>].</p><p>If the phenotype is predominantly male, the choice of male rearing is clear (see <a class="local">'Gender role change at puberty'</a> above). Some experts recommend that all infants diagnosed with steroid 5-alpha-reductase 2 deficiency be raised as males because affected subjects virilize to a variable extent later in life [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H1479418708"><span class="h3">Referral</span><span class="headingEndMark"> — </span>Given the complexity of sex assignment decisions in the newborn, we suggest that patients be treated in centers where multidisciplinary expertise in conditions affecting of sex development is available.</p><p>The issue of sex assignment is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)", section on '46,XY 17-beta-HSD and 5-alpha-reductase deficiencies'</a>.)</p><p class="headingAnchor" id="H693108660"><span class="h2">Later diagnosis</span><span class="headingEndMark"> — </span>The situation is complex when the diagnosis is made later in childhood in individuals who were raised as female. On the one hand, such girls may be aware that their sex assignment was inappropriate from early childhood and may be ready to make a change in social gender [<a href="#rid44">44</a>]. On the other hand, other individuals are comfortable as females and do not wish to change social gender. The consequence is that when the diagnosis is made later in childhood or adolescence, surgical or endocrine intervention should only be done after careful psychological evaluation of the child and consultation with the parents or caregivers [<a href="#rid8">8,45,46</a>]. The age of the subject, the sex of rearing, and the choice of social gender all influence subsequent management. (See  <a class="medical medical_review" href="/z/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)", section on 'Psychosexual issues'</a> and  <a class="medical medical_review" href="/z/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)", section on '46,XY 17-beta-HSD and 5-alpha-reductase deficiencies'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Raised as female and maintained female gender role</span><span class="headingEndMark"> — </span>In light of the frequent change in gender role from female to male (see above) [<a href="#rid30">30</a>], the decision to raise an individual as female should be made only after thorough psychologic assessment to confirm the presence of female gender identity. Once the decision has been made to maintain a female social role, management practices in many countries include:</p><p class="bulletIndent1"><span class="glyph">●</span>Gonadectomy is done before puberty to prevent or minimize virilization and to prevent development of tumors in inguinal or labial testes [<a href="#rid47">47</a>]. Clitoromegaly may be surgically corrected by an experienced surgeon to maintain the glans clitoris. If vaginal development is insufficient, vaginal depth should be enhanced by use of dilators at the appropriate age, and if this is unsuccessful, an artificial vagina should be created surgically [<a href="#rid48">48</a>]. This practice is still under debate, and any intervention depends upon social and medical standards, which vary by country. The approach may change once clearer practice guidelines become available. Alternatively, the use of gonadotropin-releasing hormone (GnRH) analogs to prevent puberty may be warranted to avoid early gonadectomy and allow shared decision-making of the affected person in adulthood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estrogen therapy appropriate for inducing and maintaining feminization should be started at the time of usual pubertal maturation or immediately after gonadectomy is performed in an adult, similar to that for treatment of primary or secondary hypogonadism in women. Such therapy is critical to promote breast development and to prevent osteoporosis. Specific studies on hormonal management are lacking. (See  <a class="medical medical_review" href="/z/d/html/5814.html" rel="external">"Approach to the patient with delayed puberty"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Raised as males or changed gender role to male</span><span class="headingEndMark"> — </span>Raising a subject as male requires complex decisions about the time and type of surgical and hormonal therapy. If patients are raised as males, surgical correction of the hypospadias and cryptorchidism (if present) should be performed by a surgeon experienced in these procedures at a time dictated by the degree of hypospadias and size of the phallus.</p><p class="headingAnchor" id="H886529036"><span class="h3">Supplemental testosterone</span><span class="headingEndMark"> — </span>Since virilization is usually less than satisfactory, even when some phallic growth occurs after the time of sexual maturation, trials of supplemental androgen are sometimes undertaken [<a href="#rid38">38,49</a>]. Although pharmacologic doses of testosterone esters may raise serum dihydrotestosterone (DHT) concentrations to the normal range and cause acne and growth of facial and body hair, phallic growth is minimal in adults, and the long-term safety of this treatment is not established.</p><p>The results are different in prepubertal subjects. In one report, as an example, pharmacologic doses of testosterone (two intramuscular doses of testosterone ester 125 mg three weeks apart) led to more than a doubling of penis size [<a href="#rid38">38</a>]. An alternate approach is to administer DHT itself, either in the form of a transdermal cream [<a href="#rid50">50</a>] or an injectable ester [<a href="#rid51">51</a>]. Both modes of DHT administration raise serum DHT concentrations [<a href="#rid50">50,51</a>], but neither preparation is commercially available and an optimal regimen or an evidence-based guideline has not been established. Recent findings indicate that DHT treatment is not able to normalize stretched penile length [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H886529030"><span class="h3">Fertility</span><span class="headingEndMark"> — </span>Sperm counts have been very low in most patients with 5-alpha-reductase 2 deficiency in whom sperm production has been measured. Sperm counts were within the low normal range in only one individual (of nine examined) from the Dominican Republic [<a href="#rid53">53</a>]. This male was able to achieve fertility with the use of intrauterine insemination [<a href="#rid54">54</a>].</p><p>Fertility has also been reported in men in whom 5-alpha-reductase deficiency caused isolated microphallus [<a href="#rid55">55</a>]. However, fertility in most affected men who have minimal detectable sperm production requires intrauterine insemination or in vitro fertilization with intracytoplasmic sperm injection [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a> and  <a class="medical medical_review" href="/z/d/html/3261.html" rel="external">"Intracytoplasmic sperm injection"</a>.)</p><p class="headingAnchor" id="H3274417774"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113605.html" rel="external">"Society guideline links: Differences of sex development"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Steroid 5-alpha-reductase 2 deficiency is a rare, autosomal recessive condition in which virilization of males during development is impaired because of inadequate conversion of testosterone to its more active intracellular metabolite dihydrotestosterone (DHT). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>46,XY individuals</strong> – The phenotype is striking because virilization of the external genitalia is impaired to varying degrees more severely than the virilization of the other parts of the male urogenital tract. As a consequence, most 46,XY persons were historically raised as females, a practice that is currently changing. (See <a class="local">'46,XY individuals'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>46,XX individuals </strong>– 46,XX females with 5-alpha reductase deficiency have a typical female phenotype with the exception of late menarche. (See <a class="local">'46,XX individuals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Definitive diagnosis requires sequencing the DNA of the gene that encodes steroid 5-alpha-reductase 2, termed <em>SRD5A2</em>. The diagnosis is suggested by the characteristic clinical features and is further supported by an elevated ratio (&gt;20) of plasma testosterone to DHT in 46,XY individuals after the age of puberty, or in infants and prepubertal subjects after administration of human chorionic gonadotropin (hCG). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sex assignment at birth</strong> – The fact that ≥50 to 60 percent of 46,XY individuals with this condition who are raised as females undergo change in gender role from female to male after the time of expected puberty complicates sex assignment in infants and small children. Careful psychological assessment should be performed prior to any irreversible interventions, most importantly surgery, to augment male or female development, particularly in children. (See <a class="local">'Initial sex assignment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Referral </strong>– Given the complexity of sex assignment decisions in the newborn, we suggest that patients be treated in centers where multidisciplinary expertise in differences of sex development (DSD) is available. (See <a class="local">'Initial sex assignment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The issues of sex assignment, psychosexual issues, and corrective genital surgery are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5807.html" rel="external">"Management of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p></p><p class="headingAnchor" id="H17092094"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges James Griffin, MD and Jean Wilson, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Frandsen A, Schousboe A. Mobilization of dantrolene-sensitive intracellular calcium pools is involved in the cytotoxicity induced by quisqualate and N-methyl-D-aspartate but not by 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionate and kainate in cultured cerebral cortical neurons. Proc Natl Acad Sci U S A 1992; 89:2590.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186:1213.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Peterson RE, Gautier T, et al. Hormonal evaluation of a large kindred with complete androgen insensitivity: evidence for secondary 5 alpha-reductase deficiency. J Clin Endocrinol Metab 1982; 54:931.</a></li><li><a class="nounderline abstract_t">Peterson RE, Imperato-McGinley J, Gautier T, Sturla E. Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Am J Med 1977; 62:170.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Gautier T, Peterson RE, Shackleton C. The prevalence of 5 alpha-reductase deficiency in children with ambiguous genitalia in the Dominican Republic. J Urol 1986; 136:867.</a></li><li><a class="nounderline abstract_t">Akgun S, Ertel NH, Imperato-McGinley J, et al. Familial male pseudohermaphroditism due to 5-alpha-reductase deficiency in a Turkish village. Am J Med 1986; 81:267.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Miller M, Wilson JD, et al. A cluster of male pseudohermaphrodites with 5 alpha-reductase deficiency in Papua New Guinea. Clin Endocrinol (Oxf) 1991; 34:293.</a></li><li><a class="nounderline abstract_t">Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav 2005; 34:399.</a></li><li><a class="nounderline abstract_t">Bertelloni S, Baldinotti F, Russo G, et al. 5α-Reductase-2 Deficiency: Clinical Findings, Endocrine Pitfalls, and Genetic Features in a Large Italian Cohort. Sex Dev 2016; 10:28.</a></li><li><a class="nounderline abstract_t">Andonova S, Robeva R, Vazharova R, et al. New Territory for an Old Disease: 5-Alpha-Reductase Type 2 Deficiency in Bulgaria. Sex Dev 2017; 11:21.</a></li><li><a class="nounderline abstract_t">Ittiwut C, Pratuangdejkul J, Supornsilchai V, et al. Novel mutations of the SRD5A2 and AR genes in Thai patients with 46, XY disorders of sex development. J Pediatr Endocrinol Metab 2017; 30:19.</a></li><li><a class="nounderline abstract_t">Batista RL, Mendonca BB. Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide. Appl Clin Genet 2020; 13:83.</a></li><li><a class="nounderline abstract_t">Moore RJ, Griffin JE, Wilson JD. Diminished 5alpha-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2. J Biol Chem 1975; 250:7168.</a></li><li><a class="nounderline abstract_t">Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci U S A 1990; 87:3640.</a></li><li><a class="nounderline abstract_t">Wilson JD, Griffin JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocr Rev 1993; 14:577.</a></li><li><a class="nounderline abstract_t">Walsh PC, Madden JD, Harrod MJ, et al. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291:944.</a></li><li><a class="nounderline abstract_t">Titus MA, Li Y, Kozyreva OG, et al. 5α-reductase type 3 enzyme in benign and malignant prostate. Prostate 2014; 74:235.</a></li><li><a class="nounderline abstract_t">Taylor RL, Arno G, Poulter JA, et al. Association of Steroid 5α-Reductase Type 3 Congenital Disorder of Glycosylation With Early-Onset Retinal Dystrophy. JAMA Ophthalmol 2017; 135:339.</a></li><li class="breakAll">The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. http://www.hgmd.cf.ac.uk/ac/index.php (Accessed on August 17, 2010).</li><li><a class="nounderline abstract_t">Maimoun L, Philibert P, Cammas B, et al. Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients. J Clin Endocrinol Metab 2011; 96:296.</a></li><li><a class="nounderline abstract_t">Sasaki G, Ogata T, Ishii T, et al. Micropenis and the 5alpha-reductase-2 (SRD5A2) gene: mutation and V89L polymorphism analysis in 81 Japanese patients. J Clin Endocrinol Metab 2003; 88:3431.</a></li><li><a class="nounderline abstract_t">Mazen I, Gad YZ, Hafez M, et al. Molecular analysis of 5alpha-reductase type 2 gene in eight unrelated egyptian children with suspected 5alpha-reductase deficiency: prevalence of the G34R mutation. Clin Endocrinol (Oxf) 2003; 58:627.</a></li><li><a class="nounderline abstract_t">Hochberg Z, Chayen R, Reiss N, et al. Clinical, biochemical, and genetic findings in a large pedigree of male and female patients with 5 alpha-reductase 2 deficiency. J Clin Endocrinol Metab 1996; 81:2821.</a></li><li><a class="nounderline abstract_t">Sinnecker GH, Hiort O, Dibbelt L, et al. Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Am J Med Genet 1996; 63:223.</a></li><li><a class="nounderline abstract_t">Kolesinska Z, Ahmed SF, Niedziela M, et al. Changes over time in sex assignment for disorders of sex development. Pediatrics 2014; 134:e710.</a></li><li><a class="nounderline abstract_t">Hiort O, Willenbring H, Albers N, et al. Molecular genetic analysis and human chorionic gonadotropin stimulation tests in the diagnosis of prepubertal patients with partial 5 alpha-reductase deficiency. Eur J Pediatr 1996; 155:445.</a></li><li><a class="nounderline abstract_t">Kumar A, Sharma R, Faruq M, et al. Spectrum of Pathogenic Variants in SRD5A2 in Indian Children with 46,XY Disorders of Sex Development and Clinically Suspected Steroid 5α-Reductase 2 Deficiency. Sex Dev 2019; 13:228.</a></li><li><a class="nounderline abstract_t">Frade Costa EM, Prado Arnhold IJ, Inacio M, Mendonca BB. Normal bone density in male pseudohermaphroditism due to 5alpha- reductase 2 deficiency. Rev Hosp Clin Fac Med Sao Paulo 2001; 56:139.</a></li><li><a class="nounderline abstract_t">Sobel V, Schwartz B, Zhu YS, et al. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab 2006; 91:3017.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Peterson RE, Gautier T, Sturla E. Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency. N Engl J Med 1979; 300:1233.</a></li><li><a class="nounderline abstract_t">Zhu H, Liu W, Han B, et al. Phenotypic and molecular characteristics in eleven Chinese patients with 5α-reductase Type 2 deficiency. Clin Endocrinol (Oxf) 2014; 81:711.</a></li><li><a class="nounderline abstract_t">Méndez JP, Ulloa-Aguirre A, Imperato-McGinley J, et al. Male pseudohermaphroditism due to primary 5 alpha-reductase deficiency: variation in gender identity reversal in seven Mexican patients from five different pedigrees. J Endocrinol Invest 1995; 18:205.</a></li><li><a class="nounderline abstract_t">Hughes IA, Houk C, Ahmed SF, et al. Consensus statement on management of intersex disorders. Arch Dis Child 2006; 91:554.</a></li><li><a class="nounderline abstract_t">Wilson JD. Androgens, androgen receptors, and male gender role behavior. Horm Behav 2001; 40:358.</a></li><li><a class="nounderline abstract_t">Milewich L, Mendonca BB, Arnhold I, et al. Women with steroid 5 alpha-reductase 2 deficiency have normal concentrations of plasma 5 alpha-dihydroprogesterone during the luteal phase. J Clin Endocrinol Metab 1995; 80:3136.</a></li><li><a class="nounderline abstract_t">Katz MD, Cai LQ, Zhu YS, et al. The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab 1995; 80:3160.</a></li><li><a class="nounderline abstract_t">Imperato-McGinley J, Gautier T, Pichardo M, Shackleton C. The diagnosis of 5 alpha-reductase deficiency in infancy. J Clin Endocrinol Metab 1986; 63:1313.</a></li><li><a class="nounderline abstract_t">Mendonca BB, Inacio M, Costa EM, et al. Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 1996; 75:64.</a></li><li><a class="nounderline abstract_t">Cheon CK. Practical approach to steroid 5alpha-reductase type 2 deficiency. Eur J Pediatr 2011; 170:1.</a></li><li><a class="nounderline abstract_t">Givens JR, Wiser WL, Summitt RL, et al. Familial male pseudohermaphroditism without gynecomastia due to deficient testicular 17-ketosteroid reductase activity. N Engl J Med 1974; 291:938.</a></li><li><a class="nounderline abstract_t">Mendonca BB, Inacio M, Arnhold IJ, et al. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 2000; 79:299.</a></li><li><a class="nounderline abstract_t">Andersson S, Moghrabi N. Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases. Steroids 1997; 62:143.</a></li><li><a class="nounderline abstract_t">Chirkov GP, Boĭkov PIa, Druzhinina MK, Todorov IN. [Biosynthesis of ribosomal RNA in rat liver cells after inhibition of protein synthesis]. Biokhimiia 1983; 48:975.</a></li><li><a class="nounderline abstract_t">Praveen EP, Desai AK, Khurana ML, et al. Gender identity of children and young adults with 5alpha-reductase deficiency. J Pediatr Endocrinol Metab 2008; 21:173.</a></li><li><a class="nounderline abstract_t">Houk CP, Damiani D, Lee PA. Choice of gender in 5alpha-reductase deficiency: a moving target. J Pediatr Endocrinol Metab 2005; 18:339.</a></li><li><a class="nounderline abstract_t">Sobel V, Imperato-McGinley J. Gender identity in XY intersexuality. Child Adolesc Psychiatr Clin N Am 2004; 13:609.</a></li><li><a class="nounderline abstract_t">Sasaki G, Nakagawa K, Hashiguchi A, et al. Giant seminoma in a patient with 5 alpha-reductase type 2 deficiency. J Urol 2003; 169:1080.</a></li><li><a class="nounderline abstract_t">Costa EM, Mendonca BB, Inácio M, et al. Management of ambiguous genitalia in pseudohermaphrodites: new perspectives on vaginal dilation. Fertil Steril 1997; 67:229.</a></li><li><a class="nounderline abstract_t">Price P, Wass JA, Griffin JE, et al. High dose androgen therapy in male pseudohermaphroditism due to 5 alpha-reductase deficiency and disorders of the androgen receptor. J Clin Invest 1984; 74:1496.</a></li><li><a class="nounderline abstract_t">Carpenter TO, Imperato-McGinley J, Boulware SD, et al. Variable expression of 5 alpha-reductase deficiency: presentation with male phenotype in a child of Greek origin. J Clin Endocrinol Metab 1990; 71:318.</a></li><li><a class="nounderline abstract_t">Keenan BS, Eberle AJ, Sparrow JT, et al. Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function. J Clin Endocrinol Metab 1987; 64:557.</a></li><li><a class="nounderline abstract_t">Sasaki G, Ishii T, Hori N, et al. Effects of pre- and post-pubertal dihydrotestosterone treatment on penile length in 5α-reductase type 2 deficiency. Endocr J 2019; 66:837.</a></li><li><a class="nounderline abstract_t">Cai LQ, Fratianni CM, Gautier T, Imperato-McGinley J. Dihydrotestosterone regulation of semen in male pseudohermaphrodites with 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab 1994; 79:409.</a></li><li><a class="nounderline abstract_t">Katz MD, Kligman I, Cai LQ, et al. Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency. N Engl J Med 1997; 336:994.</a></li><li><a class="nounderline abstract_t">Nordenskjöld A, Ivarsson SA. Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family. J Clin Endocrinol Metab 1998; 83:3236.</a></li><li><a class="nounderline abstract_t">Bourne H, Richings N, Harari O, et al. The use of intracytoplasmic sperm injection for the treatment of severe and extreme male infertility. Reprod Fertil Dev 1995; 7:237.</a></li></ol></div><div id="topicVersionRevision">Topic 7470 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1372982" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mobilization of dantrolene-sensitive intracellular calcium pools is involved in the cytotoxicity induced by quisqualate and N-methyl-D-aspartate but not by 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionate and kainate in cultured cerebral cortical neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4432067" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6801078" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hormonal evaluation of a large kindred with complete androgen insensitivity: evidence for secondary 5 alpha-reductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/835597" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3489839" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The prevalence of 5 alpha-reductase deficiency in children with ambiguous genitalia in the Dominican Republic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3740084" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Familial male pseudohermaphroditism due to 5-alpha-reductase deficiency in a Turkish village.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1831738" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A cluster of male pseudohermaphrodites with 5 alpha-reductase deficiency in Papua New Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16010463" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27070133" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 5α-Reductase-2 Deficiency: Clinical Findings, Endocrine Pitfalls, and Genetic Features in a Large Italian Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110336" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New Territory for an Old Disease: 5-Alpha-Reductase Type 2 Deficiency in Bulgaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27849622" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Novel mutations of the SRD5A2 and AR genes in Thai patients with 46, XY disorders of sex development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32346305" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/240819" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diminished 5alpha-reductase activity in extracts of fibroblasts cultured from patients with familial incomplete male pseudohermaphroditism, type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2339109" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8262007" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Steroid 5 alpha-reductase 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4413434" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24150795" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 5α-reductase type 3 enzyme in benign and malignant prostate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28253385" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association of Steroid 5α-Reductase Type 3 Congenital Disorder of Glycosylation With Early-Onset Retinal Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28253385" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association of Steroid 5α-Reductase Type 3 Congenital Disorder of Glycosylation With Early-Onset Retinal Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21147889" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843198" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Micropenis and the 5alpha-reductase-2 (SRD5A2) gene: mutation and V89L polymorphism analysis in 81 Japanese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12699446" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Molecular analysis of 5alpha-reductase type 2 gene in eight unrelated egyptian children with suspected 5alpha-reductase deficiency: prevalence of the G34R mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8768837" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical, biochemical, and genetic findings in a large pedigree of male and female patients with 5 alpha-reductase 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723114" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092939" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Changes over time in sex assignment for disorders of sex development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8789759" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Molecular genetic analysis and human chorionic gonadotropin stimulation tests in the diagnosis of prepubertal patients with partial 5 alpha-reductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32894851" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Spectrum of Pathogenic Variants in SRD5A2 in Indian Children with 46,XY Disorders of Sex Development and Clinically Suspected Steroid 5α-Reductase 2 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781593" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Normal bone density in male pseudohermaphroditism due to 5alpha- reductase 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735493" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/431680" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24665940" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Phenotypic and molecular characteristics in eleven Chinese patients with 5α-reductase Type 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7615906" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Male pseudohermaphroditism due to primary 5 alpha-reductase deficiency: variation in gender identity reversal in seven Mexican patients from five different pedigrees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16624884" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Consensus statement on management of intersex disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11534997" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Androgens, androgen receptors, and male gender role behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593415" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Women with steroid 5 alpha-reductase 2 deficiency have normal concentrations of plasma 5 alpha-dihydroprogesterone during the luteal phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593420" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3782419" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The diagnosis of 5 alpha-reductase deficiency in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606628" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Male pseudohermaphroditism due to steroid 5alpha-reductase 2 deficiency. Diagnosis, psychological evaluation, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20349245" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Practical approach to steroid 5alpha-reductase type 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4278097" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Familial male pseudohermaphroditism without gynecomastia due to deficient testicular 17-ketosteroid reductase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11039078" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9029729" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6882833" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : [Biosynthesis of ribosomal RNA in rat liver cells after inhibition of protein synthesis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422030" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gender identity of children and young adults with 5alpha-reductase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15844467" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Choice of gender in 5alpha-reductase deficiency: a moving target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15183376" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gender identity in XY intersexuality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576851" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Giant seminoma in a patient with 5 alpha-reductase type 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9022594" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of ambiguous genitalia in pseudohermaphrodites: new perspectives on vaginal dilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6480833" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : High dose androgen therapy in male pseudohermaphroditism due to 5 alpha-reductase deficiency and disorders of the androgen receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2143199" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Variable expression of 5 alpha-reductase deficiency: presentation with male phenotype in a child of Greek origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3546348" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Dihydrotestosterone heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31178538" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effects of pre- and post-pubertal dihydrotestosterone treatment on penile length in 5α-reductase type 2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8045956" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dihydrotestosterone regulation of semen in male pseudohermaphrodites with 5 alpha-reductase-2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9077378" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745434" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7480842" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The use of intracytoplasmic sperm injection for the treatment of severe and extreme male infertility.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
